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1 Drug description 
Generic/Brand name/ATC code:  
S-1, TS-1, Teysuno™/ L01BC53  
 Developer/Company:  
Taiho Pharma Europe Ltd., Sanofi-Aventis 
Description:  
S-1 (Teysuno™) is a novel oral fluoropyrimidine derivative that contains 
three substances: tegafur, gimeracil and oteracil [1]. Tegafur, the main ac-
tive substance in this pharmaceutical product, is a cytotoxic medicine that 
belongs to the anti-metabolites group. The prodrug tegafur is converted to 5-
fluorouracil (5-FU) which is responsible for interfering with enzymes in-
volved in producing new DNA. It thus inhibits the growth of cancer cells 
and eventually kills those cells. Gimeracil and oteracil support the admini-
stration of tegafur. Gimeracil inhibits the metabolism of 5-FU, resulting in 
high concentrations of 5-FU in the blood while oteracil reduces gastrointes-
tinal toxicity [1].  
S-1 is available in two different dosages (brown and white capsules). The 
white capsules consist of 20 mg tegafur, 5.8 mg gimeracil and 15.8 mg oter-
acil, whereas the brown capsules contain 15 mg tegafur, 4.35 mg gimeracil 
and 11.8 mg oteracil [1]. 
The optimal dosage of S-1 for the treatment of non-small lung cancer 
(NSCLC) as well as the best chemotherapeutic agent it should be combined 
with cannot be determined yet, as the dosing regimens which were used in 
several clinical trials varied from 40mg/m² to 60mg/m² twice a day to 
80mg/m2 once daily. However, in the majority of trials and in the only phase 
III trial, 80mg/m² of S-1 daily were administered in combination with car-
boplatin.  
For advanced gastric cancer, for which the EMA has granted market au-
thorization, 25mg/m² of S-1 should be administered twice daily in combina-
tion with cisplatin [1].  
Patients with kidney problems, severe leukopenia, neutropenia, thrombocy-
topenia or pregnant or breast feeding women should not receive S-1. Indi-
viduals suffering from severe and unexpected side effects, as well as patients 
with a deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD) 
should not receive S-1 [1].  
S-1 is an oral 
fluoropyrimidine 
most commonly used 
dosage for NSCLC: 
80mg/m2 per day  
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2 Indication 
S-1 (Teysuno™) is indicated as 1st-line therapy for patients with advanced 
NSCLC in combination with a platinum-based chemotherapy. 
3 Current regulatory status 
The EMA has not yet approved S-1 (Teysuno™) for NSCLC, but granted 
market authorization for the treatment of advanced gastric cancer in combi-
nation with cisplatin in March 2011 [1].  
In the U.S., S-1 is not approved, but it has market authorization for gastric 
cancer in Japan, South Korea, China, Singapore and Taiwan. In Japan it is 
also licensed for six additional indications (colorectal, head and neck, non-
small cell lung, metastatic breast, pancreatic and biliary tract cancers) [2]. 
4 Burden of disease 
Lung cancer is the number one cause of cancer-related deaths worldwide [3]. 
The primary risk factor for lung cancer is smoking [4]. The number of ciga-
rettes smoked per day and the number of years being a smoker has an influ-
ence on the risk of developing lung cancer, but also “second-hand smoke” is 
known to cause lung cancer [5]. Other, less frequent risk factors are the ra-
dioactive gas radon [6], asbestos [7], lung inflammation, lung scarring sec-
ondary to tuberculosis and a positive family history [8, 9]. Men are still more 
often affected by NSCLC than women, with the majority of patients being 
diagnosed at an age ≥ 65 years [10]. On average, patients are aged 71 years 
at the time of diagnosis of NSCLC. 
About 85 % of all lung cancers belong to NSCLC which can be differenti-
ated further into 2 types: non-squamous carcinoma and squamous cell carci-
noma [11]. About 3,600 people died of lung cancer and, overall, nearly 4,100 
new cases of lung cancer were diagnosed in Austria in 2008 [12]. As NSCLC 
accounts for about 85% of all lung cancer cases [13, 14] of which up to 85% 
[16] can be expected to present with advanced disease, an estimated 2,900 
persons present with advanced NSCLC per year in Austria.  
The classification of NSCLC is done according to the tumour node metasta-
ses system (TNM) which takes into account primary tumour characteristics, 
the presence or absence of regional lymph node involvement and distant me-
tastases. Four stages (I –IV) are distinguished; stage IIIB describes tumours 
which invade anatomical structures surrounding the lungs or with other tu-
mour nodules in a different lobe of the same lung. In addition, lymph nodes 
other than those closest to the affected lung are involved. Stage IV refers to 
NSCLCs which have metastasized.  
indicated in 
chemotherapy-naive 
patients with NSCLC 
not approved by EMA or 
FDA for NSCLC 
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to TNM system 
early stage disease, good 
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4 stages of NSCLC 
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The TNM system is used to guide treatment decisions [15]. In addition, pa-
tients’ performance status, the histological type of the tumour and co-
morbidities are considered for the development of a treatment regimen [16].  
Factors associated with a good prognosis are, besides early stage disease ac-
cording to the TNM system, good performance status, female gender and no 
significant weight loss [17]. Poor prognostic factors, in contrast, include bio-
logic prognostic factors like mutations of the tumour suppressor gene, the 
activation of proto-oncogene Kirsten-Rous sarcoma virus (K-ras) and other 
biological markers. For example, patients without EGFR mutations have a 
worse prognosis than those with mutations [18, 19]. Patients with stage IIIB 
and stage IV NSCLC have a median OS of 10 months and 6 months, respec-
tively [16]. 
5 Current treatment 
Treatment of patients with stage I to stage III NSCLC has a curative intent 
and comprises surgery, chemotherapy, radiation therapy or a combination of 
these treatment options. Patients with advanced tumours are treated with 
systemic therapy and/or palliative therapy. Appropriate treatment options 
for 1st –line therapy for patients with advanced disease (stage IV UICC7) are  
 Combination chemotherapy including either a 
 platinum compound (cisplatin or carboplatin) in addition to, for 
example, vinorelbine, paclitaxel, docetaxel, gemcitabine or pe-
metrexed  
 or, to avoid side-effects of platinum compounds, combinations of 
gemcitabine plus docetaxel or paclitaxel or vinorelbine, or pacli-
taxel plus vinorelbine  
 Single-agent chemotherapy: several active agents are available includ-
ing platinum compounds (cisplatin, carboplatin), taxanes (paclitaxel, 
docetaxel), vinorelbine, gemcitabine, pemetrexed, camptothecins (iri-
notecan, topotecan). However, single-agent chemotherapy is mainly 
used for elderly patients or for individuals with a compromised per-
formance status and for none of the agents superiority was estab-
lished.  
 monoclonal antibodies (bevacizumab, cetuximab) in combination 
with chemotherapy or tyrosine kinase inhibitors (erlotinib, gefitinib) 
[20].  
For patients without EGFR mutations or with unknown EGFR status, car-
boplatin or cisplatin based chemotherapy doublets either alone or in combi-
nation with a monoclonal antibody can be regarded as standard of care [20]. 
For patients with EGFR mutations, erlotinib or gefitinib are recommended 
instead of cytotoxic chemotherapy [20]. 
K-ras and other 
biological markers like 
EGFR mutations are 
poor prognostic factors 
median OS for IIIB 
NSCLC: 10 months, for 
stage IV: 6 months 
combination 
chemotherapy 
 
 
 
 
single agent 
chemotherapy 
 
 
 
monoclonal antibodies 
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6 Evidence 
In addition to a free text search, a systematic literature search was con-
ducted in Embase, Pubmed and the CRD Databases in May 2011. Overall, 
85 references were identified, of which one phase III trial [21] and 9 phase II 
trials  [22-30] were included in this report. The phase III trial evaluated S-1 
in combination with carboplatin, whereas various combinations were used in 
the phase II trials. All studies were conducted in Japan.  
6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy
Study title 
Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Nai¨ve Patients 
With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study [21] 
Study Identifier UMIN000000503, LETS Study (Lung Cancer Evaluation of TS-1) 
Authors/Sponsor Taiho Pharmaceutical Co Ldt. 
Phase III, randomized (1:1 ratio), open-label, multicentre Design 
Patient enrolment: August 2006 – May 2008 
Hypothesis Non-inferiority 
to establish the non-inferiority of S-1 plus carboplatin compared with paclitaxel plus car-
boplatin as first-line therapy in terms of overall survival (OS) in patients with advanced 
NSCLC. 
I(ntervention) carboplatin (AUC, 5) on day 1 + oral S-1 (40 mg/m2 twice per day) on 
days 1 to 14 every 3 weeks for a maximum of 6 cycles 
Treatment groups  
C(ontrol) carboplatin (AUC, 6) + paclitaxel (200 mg/m2) on day 1 every 3 weeks for 
a maximum of 6 cycles 
Inclusion criteria male and female patients between 20 to 75 years, confirmed NSCLC 
stage IIIB without any indications for radiotherapy or stage IV, no prior 
treatment, measurable disease, ECOG performance status of 0 or 1, esti-
mated life expectancy of at least 12 weeks 
Inclusion & Exclusion 
Exclusion criteria concomitant serious disease, symptomatic brain metastases, active con-
comitant malignancy, pleural effusion, cardiac effusion, or cardiac effu-
sion necessitating treatment, uncontrolled diabetes 
Overall survival 
(primary endpoint) 
OS NA 
Progression-free 
survival 
PFS NA 
Quality-of-life  QoL Functional Assessment of Cancer Therapy–Lung (FACT-L)  
Neurotoxicity subscale of the FACT/Gynecology Oncology 
Group-Neurotoxicity (GOG-Ntx) version 4.13 
Alopecia score: single item “I have been bothered with hair loss”
Endpoint and defini-
tions 
Disease control DC Best  tumour response among complete response, partial re-
sponse or stable disease that was confirmed and sustained for 
≥6 weeks 
Database lock NA 
one phase III trial 
9 phase I/II trials 
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Results and analysis 
Analysis description Planned interim analysis  
Non-inferiority of carboplatin and S-1 was to be concluded if the upper limit of the 95% CI of 
the HR was lower than 1.33; that is, the null hypothesis that the median OS of the carboplatin 
and S-1 group would be up to 3.48  months shorter than that of the carboplatin and paclitaxel 
group was analyzed.  
Patient Demographic 
and Clinical characteris-
tics 
Median age: I 64 years vs C 63 years  
Gender: Male: I 77.0% vs C 76.5% Female: I 23.0% vs C 23.5%  
Histology: Adenocarcinoma: I 69.1% vs C 69.4%; Non-adenocarcinoma: I 30.9% vs C 30.6% 
Clinical stage: IIIB I 24.1% vs C 24.2%, IV: I 75.9% vs C 75.8%  
Smoking status: Smokers: I 81.6% vs C 81.5%, Non-Smoker: I 18.4% vs C 18.5% 
ECOG PS: 0: I 31% vs C 32%, 1: I 69% vs C 68% 
Analysis Population (1) Intent-to-treat population (ITT): all patient who underwent random assignment 
Analysis Population (2) Per Protocol (PP): ITT population minus patients considered to have major violations of inclu-
sion or exclusion criteria and those who did not receive any protocol treatment. 
Treatment group 
(ITT) 
I 
 
C 
 
Number of subjects n=282 n=281 
OS (months) 
   median 
   95%CI 
 
15.2 
12.4 – 17.1 
 
13.3 
11.7 – 15.1 
1-year-survival rate 57.3 % 55.5 % 
PFS (months) 
   median  
   95% CI 
 
4.1 
3.7 – 4.7 
 
4.8 
4.2  - 5.1 
FACT-L  p=0.602 
 
41.2 
41.0 
 
38.2 
37.1 
FACT-GOG-Ntx  
at 6 weeks 
at 9 weeks 
p <0.001 
 
3.8 
3.7 
 
1.7 
1.9 
Alopecia score 
at 6 weeks 
at 9 week 
p<0.001 
71.7 73.5 
Descriptive statistics 
and variability esti-
mates 
DC rate (%) 
p=0.635 
Comparison groups (ITT) I vs C 
HR 0.928 
95% CI 0.730 to 1.179 
OS 
p-value - 
HR 0.998 
95% CI 0.837 to 1.190 
PFS 
p-value - 
Comparison groups (PP) I vs C 
HR 0.931 
95% CI 0.732 to 1.186 
Effect estimate per 
comparison 
OS 
p-value - 
Horizon Scanning in Oncology 
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HR 0.992 
95% CI 0.832 to 1.184 
PFS 
p-value - 
Subgroup analysis: Male (n= 432) I vs C 
HR 0.854 OS 
95% CI 0.657 to 1.111 
Subgroup analysis: Female (n= 131) I vs C 
HR 1.189 OS 
95% CI 0.657 to 2.150 
Subgroup analysis: Stage IIIB  (n= 136) I vs C 
HR 0.765 OS 
95% CI 0.469 to 1.249 
Subgroup analysis: Stage IV (n=427) I vs C 
HR 0.977 OS 
95% CI 0.742 to 1.286 
Subgroup analysis: Nonsmokers (n=104) I vs C 
HR 0.884 OS 
95% CI 0.429 to 1.821 
Subgroup analysis: Smoker (n=459) I vs C 
HR 0.924 OS 
95% CI 0.717 to 1.193 
Abbreviations: AUC = area under the curve, ECOG = Eastern Cooperative Oncology Group, NA = not available, 
DC = disease control, HR = hazard ratio, CI = confidence interval 
 
Table: most frequent adverse events  
Common Toxicity Cri-
teria version 3 
Outcome (%) I 
(n = 279) 
C 
(n=279) 
P-values 
Haematologic (All) 
Leukopenia 55.4 86.0 <0.001 
Neutropenia 58.3 89.6 <0.001 
Anaemia 86.7 82.4 0.165 
Thrombocytopenia 87.4 63.1 <0.001 
Non-haematologic (All) 
Nausea 62.4 49.1 0.002 
Vomiting 34.1 23.7 0.007 
Diarrhoea 32.6 20.8 0.002 
Neuropathy: sensory 15.8 81.0 <0.001 
All Grades 
 
Alopecia 9.3 76.7 <0.001 
 
Haematologic (Grade 3 or 4) 
Leukopenia 5.0 29.7 <0.001 
Neutropenia 18.3 31.9 <0.001 
Grade 3 
Anaemia 15.5 14.3 0.680 
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Thrombocytopenia 19.4 7.2 <0.001 
Non-haematologic (Grade 3 or 4) 
Nausea 1.8 2.2 0.475 
Vomiting 1.8 1.1 0.837 
Diarrhoe 3.2 1.1 0.302 
Neuropathy: sensory 0.4 2.9 0.668 
Febrile neutropenia 1.1 6.8 <0.001 
Haematologic (Grade 3 or 4) 
Leukopenia 0.4 2.9 <0.001 
Neutropenia 2.9 44.8 <0.001 
Anaemia 3.6 2.5 0.680 
Thrombocytopenia 13.3 2.2 <0.001 
Non-haematologic (Grade 3 or 4) 
Grade 4 
Febrile neutropenia 0 0.4 <0.001 
Grade 5 Death 0.4 0.4  
 
 
In this phase III trial, 564 previously untreated patients with stage IIIB/IV 
NSCLC were randomised either to carboplatin + paclitaxel or to car-
boplatin + S-1. An interim analysis was performed to evaluate if carboplatin 
and S-1 was non-inferior to carboplatin and paclitaxel in terms of overall 
survival (OS). Median OS was in the carboplatin + S-1 arm 15.2 months 
compared to 13.3 months in the carboplatin + paclitaxel arm, resulting in a 
HR of 0.928, demonstrating the non-inferiority of S-1 therapy. Results con-
sistent with these findings were also found in several subgroup analyses. The 
1-year survival rate was 57.3 % and 55.5%.  
Quality-of-life (QoL) was evaluated using the FACT-L and the FACT/GOG-
Ntx questionnaires. For the lung cancer subscale (FACT-L) no differences 
between the two treatment arms were found, but carboplatin + S-1 showed 
significant improvements in the FACT/GOG-Ntx (evaluation of chemother-
apy-induced neuropathy) and the alopecia score.  
Two deaths were reported as a result of toxicities. One patient died due to 
gastrointestinal haemorrhage in the carboplatin + S-1 arm and one death 
was associated with febrile neutropenia and pneumonia in the carboplatin + 
paclitaxel arm. 
The treatment of S-1 + carboplatin was associated with more platelet trans-
fusion and with higher rates of nausea, vomiting and diarrhoea of any grade. 
Other AEs of any grade (e.g. leukopenia, (febrile) neutropenia, neuropathy 
and alopecia) occurred more frequently in the carboplatin + paclitaxel arm 
[21]. Regarding side effects of higher grades, only thrombocytopenia was 
more often observed in the carboplatin + S-1 arm, whereas leukopenia, neu-
tropenia and febrile neutropenia of grade 3/4 were observed more often in 
the carboplatin + paclitaxel arm, but dose delays, foremost due to haemato-
logical toxicity, were considerably more frequent in the S-1 arm (52%) than 
in the comparison group (10%).   
56% patients in the carboplatin + paclitaxel arm and 61% patients in the 
carboplatin + S-1 arm discontinued treatment. Of those, 61% patients dis-
phase III trial showed 
non-inferiority in OS 
untreated stage IIIB/IV 
of NSCLC 
median OS was 15.2 
months compared with 
13.3 months, HR 0.928 
OS: S-1+ carboplatin 
non-inferior in 
comparison to 
carboplatin +paclitaxel 
in interim-analysis 
QoL evaluated by FACT-
L and FACT/COG-Ntx 
 
tolerable side effects of 
S-1 
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continued due to progressive disease in the carboplatin + S-1 group and 
52% in the carboplatin + paclitaxel arm. Fewer patients, however, stopped 
treatment by reasons of toxicity in the S-1 group (I 11% vs C 14%).  
6.2 Efficacy and safety - further studies 
Studies with S-1 + platinum compound 
In this study 29 patients received oral S-1 (65mg/m² for 14 days) and car-
boplatin in a 4 week cycle [22]. No complete response (CR) occurred, but 
partial responses (PR) in 9 patients resulted in an overall response rate of 
31.0%. The median survival was 16 months and the PFS was 4.5 months. 
Regarding toxicities, haematological adverse events of grade ≥3 were leuko-
penia (13.8%), neutropenia (10.3%), anaemia and thrombocytopenia (3.4% 
each). The only higher grade non-haematological adverse events were infec-
tions which were seen in 3.4% of all patients [22].   
55 patients were treated with oral S-1 (40 mg/m2 twice daily) for 21 consecu-
tive days. 60mg/m2 of cisplatin was administered intravenously on day 8 
[23]. Every 5 weeks this schedule was repeated. Out of the 55 eligible pa-
tients, 1 CR and 25 PR were observed, resulting in an overall response rate 
of 47%. The 1-year survival rate was 45 % and the 2-year survival rate was 
17%. At a median follow-up of 28 months, median survival time was 11 
months. Most common toxicities of grade 3 or 4 were neutropenia (29%), 
anaemia (22%) and leukopenia (6%). Anorexia of grade 3 or 4 was the most 
often observed non-haematological toxicity and occurred in 13% [23]. 
Another study investigated a combination therapy of S-1 with weekly cis-
platin [24]. 26 previously untreated patients with stage IIIB/IV NSCLC were 
treated with oral S-1 (40mg/m2 twice daily) for 21 days and three consecutive 
weekly low doses of cisplatin (25mg/m2) followed by a 2-week rest period. 6 
PR were observed but no CR, yielding an overall response rate of 23.1%. The 
median survival time was 13.4 months and the median PFS was 5.4 months. 
Haematological toxicities of grade 3 and 4 were observed in up to 15%. Most 
common non-haematological toxicities of grade ≥ 3 were diarrhoea and fa-
tigue which occurred in 8% each. No treatment-related deaths were ob-
served. [24]. 
Another study [25] assessed S-1 (40mg/m² twice daily) in combination with 
cisplatin (60mg/m²) in 40 previously untreated patients. Again, no CR re-
sponse was observed, but due to a PR in 7 patients, the overall response rate 
was 17.5%. Median survival time was 17.9 months and PFS 4.3 months. 
.Grade 3 or 4 toxicities were anaemia (15%) and leucocytopenia (7.5%). No 
grade 4 non-haematological AE was observed [25]. 
 
Studies with S-1 only 
Two phase II studies investigated S-1 only [26, 27]. Patients received 50-75 
mg/m² or 80 mg/m² daily. No CR was observed in either of the trials, but PR 
ranged between 12.5% [26]- 22.7% [27].  Median survival time was between 
8.4 months [26] to 10.2 months [27]. Grade 4 toxicities were rare in both 
studies, because only fatigue and diarrhoea occurred in 1 patient each. Most 
frequent haematological grade ≥3 AEs were leucopenia, neutropenia and 
4 phase II studies using 
S-1 + platinum 
compound all conducted 
in Japan 
 
 
different dosages of S-1 
used 
 
studies with cisplatin 
show similar results 
regarding OS (11 to 18 
months)  
no complete response 
observed 
 
no treatment related 
deaths 
haematological grade 3 
or 4 AEsin maximum of 
29% 
2 other phase II studies 
S-1 as mono-therapy 
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anaemia in up to 6.8%; anorexia and diarrhoea were the most common non-
haematological AEs of higher grades.  
 
Studies with S-1 + other chemotherapeutic regimens 
Three studies [28-30] comprising between 56 [28] and 80 patients [29] as-
sessed S-1 at doses ranging from 40mg/m² to 80mg/m². It was combined with 
doxetacel [30], irinotecan [28] or gemcitabine [29]. Median OS was between 
15 months [28, 30] and 19 months [29] and PFS ranged from about 4 months 
[29] to 5 months [28, 30]. No CR was observed in any of the trials and ORR 
were with 28% comparable. Regarding toxicities, the most frequent of grade 
≥3 AE were neutropenia (25% [28] to 73% [30]), febrile neutropenia (6% 
[29] to 17% [30]) and thrombocytopenia 11% [29] to 14% [28].  
7 Estimated costs 
No cost estimates for S-1 (Teysuno™) are available yet in Austria.  
8 On-going research 
No on-going phase III trials investigating S-1 (Teysuno™) in patients with 
NSCLC were found at ClinicalTrials.gov.  
Nevertheless, a few on-going phase I/II trials are registered: 
 NCT00874328: to determine the maximum-tolerated dose, the rec-
ommended dose, and to evaluate the response rate and toxicity of the 
S-1, irinotecan and cisplatin combination in patients with advanced 
or metastatic NSCLC. The estimated date for study completion is De-
cember 2012. 
 NCT00227578: to evaluate the effect of administration S-1 together 
with cisplatin as a first-line therapy in the treatment of patients with 
stage III or IV NSCLC that cannot be removed by surgery. Start of 
this trial was in 2005, but there is no end date mentioned yet. 
 NCT00227552: to investigate S-1 as second-line therapy in treating 
patients with un-resectable or recurrent stage III or stage IV NSCLC. 
The end of study date is unknown.  
9 Commentary  
At the moment, Teysuno™ (S-1) is not approved for the 1st-line therapy of 
advanced NSCLC, neither by the EMA nor by the FDA. However, the EMA 
approved, like several Asian countries, S-1 for gastric cancer in March 2011 
3 other phase II studies: 
combination with 
doxetacel, irinotecan or 
gemcitabine 
costs for Teysuno™ 
unknown 
might be higher than 
other treatment 
regimens 
no on-going phase III 
trials 
 
some on-going phase I/II 
studies were found 
 
not yet approved for 
NSCLC in Europe 
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[31]. In Japan, the drug is also licensed for other tumour entities including 
NSCLC [2].  
For NSCLC, several studies, mostly phase II, were found which investigated 
S-1 in different combinations and with different dosages. Only one phase III 
trial evaluated 1st-line therapy with oral S-1 + carboplatin in comparison to 
paclitaxel + carboplatin in previously untreated patients with advanced 
NSCLC. Within this trial, non-inferiority of S-1 for OS was demonstrated at 
a planned interim analysis (when final results can be expected remains un-
known), but even the authors themselves mention that the selected non-
inferiority margin of 1.33 (that is risk of death increased by 1/3 was toler-
ated) was large. Improved QoL results for S-1 were found for some scores, 
such as the alopecia score, but no difference was shown in the FACT-L 
score. Concerning AEs of higher grades, only thrombocytopenia was statisti-
cally significant more often observed in the S-1 group, whereas other AEs 
were more frequent in the comparison group, but dose delays due to haema-
tological toxicity were necessary in 52% of carboplatin and S-1 courses and 
in 10% of the carboplatin and paclitaxel courses. These findings are consis-
tent with those of the phase II studies, which assessed S-1 in combination 
with various different agents. Toxicity can thus be regarded as acceptable. 
Nonetheless, it should be mentioned that all trials were conducted in Japan. 
In addition, patients in the phase III study were, with an average age of 63 
years, younger than patients usually are at diagnosis and only patients in 
good condition were included. Estimating if S-1 is also non-inferior in frail 
and older Caucasian patients is therefore difficult. Furthermore, even 
though a subgroup analysis showed consistent results for several characteris-
tics, these analyses were not sufficiently powered. It would be thus of inter-
est to further investigate these variables as differences of efficacy of S-1 
might exist between men and women.  
In addition, the comparator of the phase III study might not reflect standard 
therapy for patients which were included in the study (i.e. adenocarcinoma, 
good performance status), because monoclonal antibodies (e.g. bevacizumab 
or cetuximab) in addition to platinum-based chemotherapy doublets are 
recommended for these patients rather than chemotherapy alone [13, 16]. 
Moreover, EGFR testing prior to initial therapy is increasingly gaining im-
portance to identify patients most likely to benefit from agents targeting the 
EGFR (e.g. gefitinib) [13], but the study did not provide information on the 
EGFR mutational status. Since superiority and not only non-inferiority in 
terms of prolonged PFS (but not for OS) was shown in phase III studies for 
gefitinib [32], it is unlikely that S-1 offers more distinct benefits to patients 
with EGFR mutations. Based on the available evidence, S-1 is an alternative 
to standard-chemotherapy only for patients not eligible for monoclonal anti-
bodies and with unknown or negative EGFR mutation status.  
Even though oral administration is usually an advantage of new therapies, 
this might not hold true in this case, since most chemotherapeutic regimens 
for NSCLC are administered intravenously every 3 weeks [16]. The S-1 reg-
imen used in the phase III study also required patients to receive intrave-
nous drugs every 3 weeks. Hence, the only advantage of a faster infusion 
time (by sparing the administration of a 2nd intravenous drug) might be out-
weighed by adherence problems when S-1 has to be taken autonomously and 
regularly at home. If S-1 replaces other intravenous agents which need to be 
administered more often, then oral administration offers an advantage.  
one phase III trial with a 
large non-inferiority 
margin 
S-1 + carboplatin is non-
inferior to paclitaxel  + 
carboplatin in terms of 
OS 
some advantages: fewer 
higher grade AEs, some 
QoL outcomes improved 
all trials conducted in 
Asian population, 
included young patients 
with excellent or good 
PS 
unknown if differences 
between men and 
women 
comparator used does 
not reflect standard 
therapy 
in addition, more 
targeted therapies 
increasingly used as 1st 
line therapy for patients 
with EGFR mutations, 
but no information on 
EGFR status for study 
population available 
oral application might 
offer advantages 
depending on therapy 
replaced but bears risk 
of adherence problems  
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An important question is how much S-1 will cost, but because of its oral ap-
plication the price might be rather high. Since NSCLC is a very common 
type of cancer, the budget impact can thus be considerable. But even without 
market authorization for NSCLC, due to its licensing for gastric cancer, S-1 
might be used off-label.  
In summary, the non-inferiority of S-1 was established in comparison to 
standard platinum-based doublet therapy and showed some advantages in 
terms of toxicities and QoL. However, the available evidence does currently 
not indicate that patients who qualify for more targeted treatment options 
will benefit from S-1, and the price is potentially higher than that for stan-
dard chemotherapeutics.  
 
costs unknown 
replacing well-
established therapy 
might not be justified 
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